Quibim, a leading health technology company pioneering imaging biomarkers for precision medicine, announced the closing of its $50 million Series A funding round. And the company has experienced remarkable growth in the number of patients analyzed by its products over the past year. This funding was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners (through the BHG I fund, created in partnership with Columbus Venture Partners), and joined by UI Investissements, and GoHub Ventures as new investors. Current investors also joined them: Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures and Leadwind (KFund’s early growth fund), and individual investors, including Tony Fadell (Build Collective Principal, Nest founder and inventor of the iPod), and Dr. Jonathan Milner (founder of Abcam).
Headed by several regulatory approvals and global commercial partnerships, patient analysis surged by 168% quarter-on-quarter. Quibim is dedicated to unlocking a complete and non-invasive understanding of every tissue point in the human body at any moment. To achieve this, the company develops foundational AI models applied to imaging that extract actionable insights from MRI, CT, and PET scans. These insights enable precise characterization of phenotypes and prediction of outcomes in areas such as oncology, immunology, neurology, and metabolic disorders.
This is the pathway toward achieving human digital twins. These dynamic models reflect and allow health monitoring, enhance patient stratification, improve the success rates of drug development programs, and enable treatment testing before application. Today, the company is building digital twins at the organ and lesion level, exemplified by solutions like QP-Brain, QP-Prostate, and QP-Liver.
But as the volume of whole-body scans and related imaging data grows, Quibim models will analyze the entire body in the coming years. The company’s vision is to catalyze this revolutionary step in healthcare by merging imaging technologies, computing, and AI.
With 170+ installations worldwide, including prestigious institutions like Mass General Brigham and Stanford, and regulatory clearances across the US, EU, UK, and other regions, Quibim’s technology bridges the gap between research, clinical practice, and drug development. Last year, Philips announced a global partnership with Quibim to integrate its AI models into MR scanners. The company also secured strategic alliances with leading biopharma giants such as Merck KGaA and Novartis.
Quibim’s product portfolio includes:
1.) QP-Prostate – The company’s flagship product is designed to enhance prostate cancer detection through an industry-leading AI-powered lesion detection CE, UKCA marked, and 510(k) cleared.
2.) QP-Brain – AI-based early-stage neurological disease quantification software for quantification of early brain atrophy and lesions. CE, UKCA marked, and 510(k) cleared.
3.) QP-Liver – Automated AI tool for MR diagnosis of diffuse liver diseases through accurately quantifying tissue fat and iron levels. CE and UKCA marked.
4.) QP-Insights – A platform to manage, store, and analyze multi-omics data in clinical trials and real-world data studies. QP-Insights is being used by global biopharmaceutical companies, academic medical centers, and research consortiums, including the European Cancer Imaging Initiative, to support Europe’s Beating Cancer Plan. QP-Insights is the platform managing the most extensive imaging datasets globally, accounting for more than 100 million medical images.
With the series A funding, Quibim is establishing a strong U.S. presence, building on its success in Europe through strategic collaborations with hospitals and pharmaceutical companies.
The company will support healthcare providers and clinical researchers in processing unprecedented data from medical scans by implementing its strategic plan and its suite of solutions already cleared by the FDA. Additionally, Quibim’s AI-powered imaging solutions will empower pharmaceutical companies by enhancing clinical trials and accelerating drug development with precise, actionable insights derived from imaging biomarkers.
KEY QUOTES:
“Quibim’s mission is to turn imaging into a catalyst for precision health, and we are deeply grateful to both our new and current investors for their support. Our global expansion into the U.S. is a critical milestone as we work with pharmaceutical leaders and healthcare providers to unlock the power of imaging to revolutionize diagnostics and improve patient outcomes.”
- Dr. Ángel Alberich-Bayarri, CEO and co-founder of Quibim
“Asabys is thrilled to support Quibim in transforming the imaging diagnostics space. Their ability to combine AI with imaging biomarker discovery addresses critical unmet needs in oncology, neurology, and beyond. We are confident that Quibim’s innovative solutions will have a profound impact on global healthcare.”
- Guillem Masferrer, Partner at Asabys Partners
“Quibim’s technology exemplifies the next wave of precision medicine. Their impressive track record with global pharmaceutical partnerships, including partnerships with companies such as Merck KGaA and Philips, exemplify Quibim’s role in transforming imaging data into valuable predictions for clinical trials and treatment planning. We expect that as Quibim develops its pipeline of companion diagnostic tools, we will see tremendous momentum for its technology and products.”
- José Mesa, Partner at Columbus and Buenavista’s representative on the Board
“The foundational research done by Quibim’s team has not only informed industry standards, but also led to the company pioneering an approach to combining radiomics and deep learning that is now a standard of its own. This platform approach was novel at the time of our first investment and proved to be the right strategy for rapid scale-up.”
- Pierre Socha, Partner at Amadeus Capital Partners
“Excited that Quibim’s AI enabled insights from MRI, CT, and PET scans are coming to the US! Their FDA approved precision analysis is already being used by doctors to detect early signs of diseases like cancer and help measure treatment response. Quibim has truly advanced precision medicine around the world!”
- Tony Fadell Build Collective Principal and Nest Founder
